 |
인쇄하기
취소
|
Kanarb sales at brisk pace
Boryung Pharmaceutical, one of Korea’s leading drug makers, is enjoying brisk sales of its new antihypertensive drug, Kanarb.
Sales of Dong-A’s antihypertensive agent recorded over 1.3 billion won since its release in March 2011.
If Kanarb is successfully landed in general hospitals, its sales will gain momentum, surpassing 1.0 billion won on a monthly basis.
Market watchers say Kanar...
Sales of Dong-A’s antihypertensive agent recorded over 1.3 billion won since its release in March 2011.
If Kanarb is successfully landed in general hospitals, its sales will gain momentum, surpassing 1.0 billion won on a monthly basis.
Market watchers say Kanar...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.